-

Thermo Fisher Scientific Named 2022 Eagle Award Winner for Clinical Research Site Partnerships

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded the Eagle Award for the second consecutive year for its outstanding leadership, professionalism, integrity and dedication to advancing the clinical research profession through strong partnerships with research sites.

The Eagle Award is a highly regarded industry honor from the Society for Clinical Research Sites (SCRS) that recognizes the top clinical research organization (CRO) for exemplifying a site-focused approach to clinical trial management. SCRS site members nominated companies based on their experiences working with CROs serving the site and patient community, and the PPD clinical research business won the title based on votes from the global site community.

“This prestigious award reflects our focus on supporting and connecting with our site partners, which in turn helps enable us to best serve our customers in pursuit of their clinical research initiatives,” said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “Our close relationships with research sites contribute to our ability to help deliver on the ambition we all share – helping deliver life-changing therapies to patients around the globe.”

The PPD clinical research business draws on decades of experience in collaborating with leading research sites and site networks worldwide to advance biopharmaceutical and biotech customers’ development programs. For investigators and physician practices new to clinical research, the business offers SiteCoach, a customized training program designed to help them navigate the complexities of patient recruitment, educate patients on their options and streamline trial administration. Additionally, the business offers Accelerated Enrollment Solutions (AES), providing customers access to its dedicated site network.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Nadine Maeser
(910) 558-4779
Nadine.Maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded the 2022 Eagle Award.
Release Versions

Contacts

Media Contact Information:
Nadine Maeser
(910) 558-4779
Nadine.Maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom